Cullinan Therapeutics And Taiho To Present Phase 2b Results From REZILIENT1 Trial Of Zipalertinib In Previously Treated EGFR ex20ins NSCLC At ASCO 2025

Author: Benzinga Newsdesk | May 22, 2025 05:33pm

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who have received prior therapy. These data will be presented on Sunday, June 1 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as an oral presentation during the "Lung Cancer – Non-Small Cell Metastatic" session from 9:00 AM-9:12 AM CDT (Abstract #8503).

Posted In: CGEM